Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.51 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 8/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13748777 | 0.81 | MAPT (0.39) | IMPDH2IMPDH1ALDH1A1KDM4EUSP2 | |
| SCHEMBL13748003 | 0.81 | IMPDH2 (0.50) | IMPDH2IMPDH1ALDH1A1KDM4EUSP2 | |
| SCHEMBL13748804 | 0.81 | NPC1 (0.40) | IMPDH2IMPDH1ALDH1A1KDM4EUSP2 | |
| SCHEMBL3699913 | 0.76 | IMPDH2 (0.49) | IMPDH2IMPDH1ALDH1A1KDM4EUSP2 | |
| SCHEMBL13748975 | 0.76 | AKR1B1 (0.42) | IMPDH2IMPDH1ALDH1A1KDM4EUSP2 | |
| SCHEMBL7064467 | 0.76 | MAPT (0.53) | IMPDH2IMPDH1ALDH1A1KDM4EUSP2 | |
| SCHEMBL31124656 | 0.76 | MAPT (0.53) | IMPDH2IMPDH1ALDH1A1KDM4EUSP2 | |
| SCHEMBL15389432 | 0.76 | ALDH1A1 (0.52) | IMPDH2IMPDH1ALDH1A1KDM4EUSP2 | |
| SCHEMBL12957782 | 0.76 | ALDH1A1 (0.52) | IMPDH2IMPDH1ALDH1A1KDM4EUSP2 | |
| SCHEMBL13748190 | 0.75 | AKR1B1 (0.44) | IMPDH2IMPDH1ALDH1A1KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835423-B2 | Azepine inhibitors of janus kinases | INCYTE CORPORATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140031344-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2014-01-30 | — | — | US | disclosed |
| US-8563541-B2 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120329782-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2012-12-27 | — | — | US | disclosed |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329782-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | IMPDH2 1995/4885IMPDH1 1471/4885ALDH1A1 3705/4885 |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | IMPDH2 1995/4885IMPDH1 1471/4885ALDH1A1 3705/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | IMPDH2 1995/4885IMPDH1 1471/4885ALDH1A1 3705/4885 |
| US-20140031344-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | IMPDH2 1995/4885IMPDH1 1471/4885ALDH1A1 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.